Peijia Medical

What Peijia Medical does

Peijia Medical Limited (HKEX: 9996) is a Chinese interventional medical device company founded in 2012 and headquartered in Suzhou Industrial Park, Jiangsu Province. The company develops, manufactures, and commercializes high-end devices across two complementary therapeutic areas: structural heart disease (transcatheter aortic valve replacement, transcatheter edge-to-edge mitral repair, and transcatheter tricuspid valve replacement) and neurovascular intervention (micro guidewires, microcatheters, coils, stent retrievers, aspiration catheters, and flow diverters). Its core technology stack combines proprietary valve leaflet processing (non-aldehyde crosslinking, ultra-low temperature vacuum freeze-drying), in-house mechanical engineering (e.g., GeminiOne sliding groove, TaurusMax adjustable-bend delivery, Fastunnel zero-exchange balloon microcatheter), and licensed global technologies (JenaValve's Trilogy/TaurusTrio for aortic regurgitation, HighLife SAS's transseptal mitral valve replacement, inQB8's MonarQ tricuspid system). As of 2025 the company has 29 commercialized products, 7 NMPA innovative-device designations, 430+ global patent applications, and an internal R&D team of 133 staff.

The business model is hardware sales of regulated medical devices to hospital customers in China. Peijia sells its transcatheter valve portfolio through a direct sales force covering 720+ hospitals as of H1 2025 (up from ~650 in 2024), while its neurointerventional portfolio is sold through a hybrid direct/dealer network covering approximately 2,100 hospitals across all 31 Chinese provinces and municipalities. Pricing is per-procedure device sale; specific price points are not publicly disclosed, but domestic products are positioned at meaningful discounts to imported alternatives (e.g., Jasper SS coils at approximately half the imported price). Revenue scaled from RMB 250.8M in 2022 to RMB 712.9M in 2025 (+15.8% YoY), with FY2025 marking first-ever TAVR segment commercial profit (RMB 29.1M in H1 2025) and a 86.6% YoY profit increase in the neurointerventional segment. International expansion is underway via FDA 510(k) clearance of DCwire (March 2026, first US product), EU MDR CE Mark submission for GeminiOne (February 2026), and global clinical studies for MonarQ TTVR.

Name

Peijia Medical

Legal name

Peijia Medical Limited

Website

https://peijiamedical.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Peijia Medical (HKEX: 9996) is a Suzhou-headquartered Chinese interventional medical device company developing and commercializing transcatheter valve replacement/repair products (aortic, mitral, tricuspid) and a comprehensive neurointerventional portfolio (coils, catheters, guidewires, stent retrievers), serving 720+ hospitals directly and 2,100+ via dealers across China, with expanding US and EU market access.

Ownership category

akta.pro rank

Product category

Interventional Cardiovascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industries

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Structural heart devices
• Neurointerventional devices
• Transcatheter aortic valve
• Stroke intervention products
• Cardiovascular medical devices

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Transcatheter Valve Therapeutic Business: Revenue from sale of transcatheter aortic valve replacement (TAVR) products and related accessories including TaurusOne, TaurusElite, TaurusMax, TaurusTrio, TaurusAtlas, and related accessories. This segment achieved its first-ever commercial profit of RMB 29.1 million in H1 2025 and grew revenue 40.1% to RMB 259.9 million in 2024.
2. Neurointerventional Business: Revenue from sale of neurointerventional devices including micro guidewires, microcatheters, guide catheters, stent retrievers, aspiration catheters, balloon guide catheters, coils, and other access products. This segment achieved 86.6% year-on-year profit increase to RMB 97.2 million in 2025, and reached its first full-year profitability of RMB 52.1 million in 2024.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Peijia Medical develops and manufactures high-end interventional medical devices for structural heart disease and cerebrovascular interventions. Its portfolio spans transcatheter aortic valve replacement (TAVR) systems, transcatheter mitral and tricuspid repair/replacement devices, and a full suite of neurointerventional products including coils, stent retrievers, aspiration catheters, balloon guide catheters, micro guidewires, and microcatheters used in hemorrhagic and ischemic stroke treatment.

Product overview

Peijia Medical is a medical device company specializing in high-end devices for structural heart disease and cerebrovascular intervention. The company operates two main business segments: Transcatheter Valve Therapeutics (TAVR and related products including TaurusOne®, TaurusElite®, TaurusMax®, TaurusTrio®, TaurusNXT®, HighLife® TMVR, GeminiOne® TEER, and MonarQ® TTVR) and Neurointerventional Business (covering hemorrhagic stroke products like Jasper® coils, NRcoil™, Presgo® coils; acute ischemic stroke products including Syphonet® stent retriever, Tethys AS® aspiration catheter, Fluxcap® balloon guide catheter; ICAS products such as Fastunnel® delivery balloon catheter, SacSpeed® balloon catheter; and access products like DCwire™ micro guidewire, Tethys® catheter, Heralder® catheters, Presgo® microcatheter/micro guidewire). The company has established a comprehensive product portfolio covering aortic, mitral, and tricuspid valve interventions, as well as complete neurointerventional solutions for stroke treatment.

Differentiator

Problem solved

Functional benefit

Brands

• 加奇生物 (Achieves Medical): Neurovascular intervention subsidiary focused on hemorrhagic stroke, ischemic stroke, and access products including coils, catheters, and micro guidewires
• Taurus
• GeminiOne
• DCwire
• Presgo
• Jasper
• Tethys
• Heralder
• Fastunnel
• Syphonet
• Fluxcap

Products and services

• TaurusOne Transcatheter Aortic Valve System First-generation self-expanding TAVR system for treating severe aortic stenosis, featuring bovine pericardial leaflets, nitinol stent, and anti-paravalvular leak design. Sold to hospitals with cardiac catheterization labs.
• TaurusElite Transcatheter Aortic Valve System Second-generation retrievable TAVR system inheriting TaurusOne valve design with bovine pericardial leaflets and adding a retrievable delivery system for multiple repositioning during implantation. Sold to hospitals.
• TaurusMax Transcatheter Aortic Valve System Third-generation TAVR system with adjustable bending delivery system and three metal markers for commissural alignment, improving aortic arch crossing, valve crossing, and valve coaxiality. Sold to hospitals.
• TaurusTrio Transcatheter Aortic Valve System Dedicated TAVR system for treating severe aortic regurgitation with unique positioning key design that clamps native leaflets for precise positioning and anchoring. Sold to hospitals.
• TaurusNXT Non-Aldehyde Crosslinking Dry Valve TAVR System Third-generation TAVR system applying non-aldehyde crosslinking valve leaflet biological processing technology and ultra-low temperature vacuum freeze-drying for pre-loading, addressing valve durability and reducing surgical preparation time. Sold to hospitals.
• GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System Transcatheter Edge-to-Edge Repair system for mitral regurgitation featuring sliding groove mechanism, independent leaflet grasping design, auto-locking mechanism, and multi-angular detachment capability. Sold to hospitals.
• HighLife Transcatheter Mitral Valve Replacement System Mitral valve replacement system using Valve-in-Ring concept with annular fixation and transseptal delivery. Sold to hospitals.
• MonarQ Transcatheter Tricuspid Valve Replacement System Transcatheter tricuspid valve replacement system with biodynamic attachment system, developed in partnership with inQB8 Medical. Sold to hospitals.
• Jasper Intracranial Electrolytic Detachable Coil Electrolytic detachable coil for intracranial aneurysm embolization with platinum-tungsten alloy coil and 304V stainless steel delivery wire. Sold to hospitals with neurointerventional capabilities.
• NRcoil Detachable Coil Detachable coil system for aneurysm embolization, available in helical and complex types. Sold to hospitals with neurointerventional capabilities.
• Syphonet Stent Retriever Stent retriever for acute ischemic stroke treatment featuring head-end net design for enhanced thrombus capture and prevention of fragmentation escape. Sold to hospitals.
• Tethys AS Thrombectomy Aspiration Catheter Large lumen aspiration catheter for acute ischemic stroke treatment with 0.071in lumen design for improved thrombus capture. Sold to hospitals.
• Fluxcap Balloon Guide Catheter Balloon guide catheter with compliant balloon for proximal flow control during thrombectomy procedures. Sold to hospitals.
• Fastunnel Delivery Balloon Dilatation Catheter Combined balloon microcatheter device for ICAS treatment enabling zero-exchange technique, reducing procedure steps from 12 to 5-7 and cutting procedure time by over 40%. Sold to hospitals.
• DCwire Micro Guidewire Steerable micro guidewire with shapeable tip, hydrophilic coating, and multi-layer microstructure for precise control and easy superselection in neurovascular procedures. Sold to hospitals.

Quantifiable outcome

• TaurusTrio achieved 99.1% technical success rate and 0% all-cause mortality at 30 days, 0% moderate or greater paravalvular leak at one year in ALTER-AR study
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Achieved Medical Limited (加奇生物/Achieva Medical)coreTechnology or Integration · 17 March 2026Achieved Medical Limited, a wholly-owned subsidiary of Peijia Medical, designed and developed the DCwire Micro Guidewire which received FDA 510(k) clearance in March 2026. Achieva Medical operates as the neurointerventional business unit of Peijia Medical and has developed 16 commercialized neurointerventional products.
• HighLife SAScoreStrategic or Co-development Partner · 9 February 2026HighLife SAS serves as Peijia Medical's European partner for the GeminiOne TEER system. Peijia submitted EU MDR CE Mark registration application for GeminiOne in February 2026. The partnership leverages HighLife's regulatory and commercial expertise in Europe. Separately, HighLife and Peijia have an existing collaboration on the HighLife TSMVR (transcatheter mitral valve replacement) system, which received FDA Breakthrough Device Designation in April 2025.
• JenaValve Technology Inc.coreOEM/ Whitelabel/ Licensing Partner · 11 December 2025JenaValve Technology granted Peijia Medical an exclusive license for the Trilogy/TaurusTrio transcatheter aortic valve system for the Greater China region. TaurusTrio received NMPA approval in December 2025 as China's first dedicated interventional treatment for severe aortic regurgitation. The product is developed under exclusive license from JenaValve. Peijia has completed technology transfer and local manufacturing of the product in China.
• Sutra Medical Inc.minorStrategic or Co-development Partner · 12 September 2025Peijia Medical holds a strategic investment in Sutra Medical Inc., which is developing the Sutra Hemi-valve transcatheter mitral valve repair system. Peijia Medical is Sutra's second largest shareholder. The first human (FIM) clinical trial implantation was completed in September 2025 on an 83-year-old high-risk patient in New Zealand.
• Bella Bella Pharmaceutical (Shanghai) Trading Co., Ltd. (贝朗医疗)minorChannel Partner/ Reseller/ Distributor · 29 August 2024Peijia Medical subsidiary Jiaqi Biological (加奇生物) signed a cooperation agreement with Bella Bella Pharmaceutical for intracranial interventional 'no-implantation' new journey, expanding the product portfolio in the intracranial intervention field.
• Jiangsu Nuanyang Medical Devices Co., Ltd. (江苏暖阳医疗器械有限公司)minorChannel Partner/ Reseller/ Distributor · 29 August 2024Peijia Medical subsidiary Jiaqi Biological signed an exclusive distribution agreement with Jiangsu Nuanyang for the YonFlow flow-directed intracranial aneurysm treatment device in Greater China for 8 years. Nuanyang Medical independently developed China's first fully retrievable flow-directed stent system.
• NowYon MedicalminorChannel Partner/ Reseller/ Distributor · 28 August 2024Peijia Medical's wholly-owned subsidiary Achieva Medical entered into an exclusive distribution agreement with NowYon Medical for the YonFlow flow diverter in Greater China. The YonFlow is the world's first retrievable stent system after complete release, received innovative medical device designation from China's NMPA in January 2023, and its registration application is pending approval.
• Fujian Medical Technology Innovation Joint Laboratory (苏州市介入医疗技术创新联合体)coreStrategic or Co-development Partner · 28 December 2023Peijia Medical leads the Suzhou Municipal Interventional Medical Technology Innovation Joint Laboratory, established December 2022, the first eco-integration innovation joint body in Suzhou's biomedical field. Members include renowned universities, hospitals, innovative leading enterprises, and life science industry incubation, operation and investment platforms. The joint laboratory has invested over 45 million yuan, obtained 1 new product approval, produced 2 new materials, achieved 3 project progress milestones, built 4 innovation platforms, invested in 5 innovative enterprises, incubated 6 projects, and applied for 24 patents.
• inQB8 Medical Technologies LLCcoreStrategic or Co-development Partner · 10 March 2022Peijia Medical partnered with U.S. medical device incubator inQB8 to co-develop the MonarQ transcatheter tricuspid valve replacement (TTVR) system. Peijia Medical holds global rights to the MonarQ product. The first human implantation was completed in Denmark in 2022 and the global clinical study first patient was implanted in 2025.
• Suzhou Industrial Technology Research Institute of Interventional Medical Technology (苏州市产业技术研究院介入医疗技术研究所)coreStrategic or Co-development Partner · 18 January 2022Co-founded by Peijia Medical, Suzhou Industrial Technology Research Institute, and Suzhou Industrial Park Management Committee. A life science industry incubation, operation and investment platform focused on interventional medical technology, discovering, investing, and integrating globally medical projects with disruptive innovative technologies. Has incubated 5 companies covering application software, polymer materials, and intelligent equipment.

Scale indicators7 records

Recent moves10 records

Expansion highlights7 records

Broad incumbents

• Stryker (Neurovascular): Acquired Cerenovus and Ischemic Stroke franchise; competes in global stroke intervention space (stent retrievers, coils, flow diverters). Direct competitor to Peijia's neurovascular portfolio outside China and benchmark for global neurovascular expansion.
• Edwards Lifesciences: Global TAVR market leader (Sapien platform) and dominant structural heart incumbent. Competes with Peijia in higher-tier Chinese hospitals and is the global benchmark for TAVR technology. Sets the R&D and clinical evidence bar that Peijia must meet.
• Medtronic: Global structural heart and neurovascular incumbent (CoreValve/Evolut TAVR, Solitaire/Skyflow neurovascular). Competes broadly with Peijia across both segments and is the founder/CEO Zhang Yi's former employer. Represents the long-term competitive benchmark.
• Abbott (Structural Heart): Global structural heart leader (Portico, Navitor TAVR platforms) and the largest player in mitral repair (MitraClip TEER). Competes with Peijia in premium-tier Chinese hospitals and represents the global standard for TEER and TMVR technologies.

Emerging players

• HighLife SAS: French transcatheter mitral valve replacement (TSMVR) developer. Peijia's European partner for GeminiOne TEER and co-developer of HighLife TSMVR (FDA Breakthrough Device). Comparable in mitral/tricuspid space and serves as Peijia's EU regulatory and commercial channel.
• JenaValve Technology: European transcatheter aortic valve developer focused on aortic regurgitation indication. Peijia's exclusive Greater China licensee for the Trilogy/TaurusTrio AR-dedicated TAVR. Both a licensor and a competitor in the AR indication globally.

Direct peers

• Venus Medtech (Hangzhou) Inc. Hong Kong-listed Chinese TAVR pioneer (2500.HK) and historically the leading domestic TAVR player. Direct competitor across aortic, mitral, and tricuspid valves, targeting the same Chinese tertiary hospitals as Peijia. Most relevant peer for structural heart segment.
• Penumbra, Inc. U.S. neurovascular and thrombectomy specialist (aspiration catheters, stent retrievers, coils). Directly comparable to Peijia's Achieva Medical subsidiary in product categories and use cases (acute ischemic stroke, cerebral aneurysm). Useful comp for global neurovascular expansion.
• Inari Medical: U.S. venous thromboembolism and thrombectomy specialist (FlowTriever, ClotTriever). Comparable to Peijia's Tethys AS aspiration catheter and Syphonet stent retriever in mechanism and clinical use case. Useful comp for neurovascular/embolization growth economics.
• MicroPort CardioFlow Cardiovatec Co. Shanghai-listed TAVR/structural heart spin-off of MicroPort Scientific (1302.HK). Competes with Peijia across the Taurus and VitaFlow valve families in the Chinese structural heart market. Closely comparable in business model and end markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/peijia-medical-suzhou-co-ltd

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peijia Medical